Currently, healthy animal models play a critical role in the safety evaluation of a drug or health product. However, pharmaceutical companies and regulatory authorities are becoming increasingly interested in the use of animal models of disease (AMD) to better understand the potential risk of a diseased population. Recent publications and recommendations for the use of these models by regulators make the growing interest of the application of AMD highly evident.